Biotech, Food, Drug

The food we eat and the medicine we put into our bodies are highly regulated by a variety of government agencies. In the United States by the Food and Drug Administration (FDA) and the United States Department of Agriculture (USDA) regulate the processes by which food makes its way to the grocery store and medicine is approved for consumer use.  As the science grows more complex behind the pharmaceutical and food industry, interpretation of the regulations in place is becoming more nuanced.  Overseas, these industries are regulated by a variety of agencies; for example, the Minister of Agriculture in Canada, Centre for Food Safety in Hong Kong, and the Committee of Environmental, Public Health and Food Safety (EU), are among the many governing-bodies which regulate biotechnology, food, and drugs throughout the world.

The National Law Review is your free online resource to agency news, emerging topics in food and drug, and the latest in biotechnology updates. From nanotechnologies being used in research, to regulations of imported foods coming into the US from overseas or the development of medical devices and drugs, readers can find expert legal analysis of the developments in the industry, as well as reports on changes within the agencies that regulate these industries. The National Law Review also covers topics related to licensing, Food Safety and Inspection Services (FSIS), food and beverage regulation in the US and worldwide, nutrition labeling, and country of origin labeling guidelines.

With recent legislation being passed throughout the US in relation to marijuana use, both for recreational and medicinal purposes, readers will also find up-to-date information, litigation, and news coming from this area of interest as well. Regulations in California for labeling and proper sales of marijuana, to use in different states, or internationally, as well as rules for promoting and advertising marijuana are also covered on the site. Additionally, the development and changing landscape of tobacco use to include vaping, and how e-cigarettes and vaping are regulated, is also covered by NLR authors.

Readers who are interested in food safety, inspection, imports into the US, and regulations, these topics are covered regularly on The National Law Review as well. New legislation from the FDA, USDA, Department of Agriculture, and international bodies, are covered on the site. If you are looking for details on new nutrition-labeling regulations or health risks of consuming certain imported foods, you will find these topics, and many more, on The National Law Review.

For hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis Twitter feed, and sign up for complimentary e-news bulletins.

Custom text Title Sort descending Organization
Feb
7
2015
21st Century Cures Discussion Draft Act Proposes Changes to Medical Device Regulation Covington & Burling LLP
Dec
15
2016
21st Century Cures: Examining Provisions for Streamlining FDA Regulations for Clinical Research in Title III McDermott Will & Emery
Jan
6
2017
21st Century Cures: Food and Drug Administration (FDA) Drug Provisions McDermott Will & Emery
Dec
16
2016
21st Century Cures: Modernizing Public and Private Research McDermott Will & Emery
Aug
9
2018
23 California DAs Obtain $1.5 Million Settlement for Deceptive Biodegradable Claims Keller and Heckman LLP
Sep
29
2014
3 Ways to Protect Our Farmers This Fall U.S. Department of Labor
May
13
2016
3-D Printing and the Regulatory Future of Home Remedies: Pharma to Table New York University School of Law
Mar
10
2015
3-D Printing Guidance Only a B-List Priority for FDA Epstein Becker & Green, P.C.
Dec
17
2014
30 Projects Announced to Support Michigan Specialty Crop Growers Varnum LLP
Feb
6
2020
30,000 Cannabis Users’ Data Exposed Robinson & Cole LLP
Feb
24
2020
340B Ceiling Price Transparency – HRSA Now Requiring Pharmaceutical Manufacturers to Issue Refunds to Covered Entities for Overcharges Mintz
Aug
16
2017
340B Covered Entities Beware: CMS Proposes Drastic Drug Reimbursement Rate Cuts Polsinelli PC
Feb
2
2023
340B Covered Entities May See Access Changes to Contrast Media, Radiopharmaceuticals and Other Products McDermott Will & Emery
Apr
3
2019
340B Drug Ceiling Prices Now Available Dinsmore & Shohl LLP
Jul
2
2021
340B Drug Pricing Discount Program Update: HRSA Now Demands That Drug Manufacturers Provide 340B Discounts To Contract Pharmacies Amid Ongoing Litigation Sheppard, Mullin, Richter & Hampton LLP
Mar
19
2021
340B Drug Pricing Program 2021 Outlook [PODCAST] K&L Gates
Jul
19
2018
340B Drug Pricing Program Litigation Update: American Hospital Association, Et Al. v. Azar Sheppard, Mullin, Richter & Hampton LLP
Apr
18
2016
340B Drug Pricing Program: HRSA Reopens Comment Period for 2015 Proposed Rule Squire Patton Boggs (US) LLP
Sep
15
2014
340B Federal Drug Pricing Program September Update: Self-Disclosures McDermott Will & Emery
Dec
19
2022
340B Hospital Reimbursement Update – Underpayments and the Need to Act Now Polsinelli PC
Mar
31
2021
340B in 2021: What Covered Entities and Their Partners Need to Know Now Recap McDermott Will & Emery
Feb
28
2020
340B In The Spotlight – CMS 340B Acquisition Cost Survey Proposal & President’s Budget Polsinelli PC
May
28
2014
340B Orphan Drug Rule Invalid Faegre Drinker
Dec
13
2019
340B Program-Participating Hospitals Object to CMS’s Proposed Cuts to 340B Program Reimbursement: CMS’s Recent Information Collection Request Sheppard, Mullin, Richter & Hampton LLP
Aug
4
2020
340B Rate Cuts Are Legal, D.C. Circuit Court Holds Mintz
May
22
2019
340B Rate Cuts: DC Court Enjoins and Remands CMS’ 2018 and 2019 Reductions for Hospital Outpatients Foley & Lardner LLP
Jun
23
2014
340B Registration Changes: Re-enrollment of Currently Participating Facilities and Eligibility Based on Amended Cost Reports McDermott Will & Emery
Apr
12
2024
340B Remedy Rule and Medicare Advantage Rates: Navigating Shifting Payments McDermott Will & Emery
Aug
13
2020
340B Update: Appellate Court Upholds 340B Payment Reduction as CMS Proposes Further Reductions for 2021 [Podcast] K&L Gates
Apr
27
2020
340B Update: CMS Opens Acquisition Cost Data Survey for 340B Hospitals K&L Gates
Sep
26
2020
340B UPDATE: Congress and the Administration Respond to Drug Manufacturers' 340B Contract Pharmacy Actions K&L Gates
Jul
7
2021
340B Update: Delaware Court Denies 340B Program Statute Requiring Contract Pharmacy Arrangements K&L Gates
Jan
18
2017
340B Update: HRSA Finalizes 340B Pricing & Penalties for Drug Manufacturers K&L Gates
Jul
21
2020
340b Update: HRSA Indicates It Lacks Authority to Enforce 340b Program Guidance K&L Gates
May
26
2021
340B Update: HRSA Issues Final Warning Letter to Pharmaceutical Manufacturers that Their Contract Pharmacy Actions Violate 340B Statute K&L Gates
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins